We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Research Makes Flu Virus Visible to Naked Eye

By LabMedica International staff writers
Posted on 16 May 2017
Researchers have discovered a way to make influenza visible to the naked eye by engineering fluorescent dye molecules to target a specific enzyme of the virus. More...
The team was able to develop a prototype test kit that detects influenza in samples using a handheld lamp or blue laser pointer, and that even helps determine if a given antiviral therapy will likely be effective.

The scientists, from University of Notre Dame, created a new method to detect neuraminidase, which is located on the surface of the virus. They began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. They then used test samples that mimicked that of an infected patient, and spiked the samples with neuraminidase that had been purified from the virus. Emission of red fluorescent light from a sample is a positive indication of the influenza virus, blue signals a negative result.

While still a prototype, with optimization the diagnostic could potentially be developed for use in point-of-care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.

The same process also allowed them to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.

Following validation of enzyme recognition, the team tested the dye with two antiviral drugs used to treat influenza (Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu). Both antivirals are neuraminidase inhibitors. Antiviral drug was added to samples containing dye and neuraminidase. Upon illumination, red fluorescence indicated the enzyme was still active, whereas blue indicated the drug failed to inhibit the enzyme. For patient samples, blue fluorescence would indicate the neuraminidase activity had been blocked, presenting an effective treatment option.

“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said study leader Bradley Smith, professor at Notre Dame.

The study, by Liu W et al, was published April 20, 2017, in the Journal of the American Chemical Society.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.